Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...

The approval was based on data from an open-label, phase 3 study that assessed Ultomiris in 13 patients 9 through 17 years of age with PNH. The Food and Drug Administration (FDA) has expanded the ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an intravenous ...

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its ...

“ We are proud to bring ULTOMIRIS to patients suffering from this devastating disease less than a year after reporting our positive Phase 3 data,” said John Orloff, M.D., Executive Vice President and ...

Ultomiris (ravulizumab-cwvz) is a brand-name injection that’s prescribed for certain rare diseases. As with other drugs, Ultomiris can cause side effects, such as upper respiratory tract infection and ...

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with ...

Ultomiris (ravulizumab-cwvz) is a prescription drug used to treat certain rare inflammatory conditions. Ultomiris can cause side effects that range from mild to serious. Examples include headache, ...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS (R) (ravulizumab-cwvz) in adults with ...

Alexion Pharmaceuticals has wasted no time converting patients to its next-generation rare disease med Ultomiris. Now, it's looking to make the switch to its Soliris successor a little easier, thanks ...

– Company will conduct further analysis of trial data to determine next steps – – No new safety findings were observed for ULTOMIRIS use in COVID-19 – BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals ...